SCHEMBL20934833

SCHEMBL20934833

Nc1nc(Cl)nn2c(Br)cnc12

nearest known ligand 0.38

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 1/20 0.38
CSNK1A1 P48729 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15410163 0.81
SCHEMBL19747058 0.79 CSNK1D (0.38)
SCHEMBL24490808 0.79 MAPT (0.35)
SCHEMBL20940165 0.75
SCHEMBL19748431 0.75
SCHEMBL19748127 0.75 CSNK1D (0.31)
SCHEMBL19748398 0.73 CSNK1D (0.38)
SCHEMBL19748848 0.71 TDP1 (0.35)
SCHEMBL23631073 0.71
SCHEMBL25214068 0.70 GAA (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12516065-B2 Tertiary alcohols as PI3K-γ inhibitors INCYTE CORPORATION (US) 2026-01-06 US disclosed
US-12281119-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist BEIGENE, LTD. (KY) 2025-04-22 US disclosed
CN-113454086-B Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists 百济神州有限公司 2025-03-14 CN disclosed
US-20240228498-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS INCYTE CORPORATION 2024-07-11 US disclosed
CN-118063470-A Condensed imidazole derivatives substituted with tertiary hydroxyl groups as PI 3K-gamma inhibitors 因赛特公司 2024-05-24 CN disclosed
US-11926630-B2 Tertiary alcohols as PI3K-γ inhibitors INCYTE CORPORATION (US) 2024-03-12 US disclosed
EP-3921320-B1 IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST BEIGENE LTD (KY) 2024-03-06 EP disclosed
CN-111542526-B Condensed imidazole derivatives substituted with tertiary hydroxyl groups as PI 3K-gamma inhibitors 因赛特公司 2024-01-09 CN disclosed
US-20220213107-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS INCYTE CORPORATION 2022-07-07 US disclosed
US-20220213107-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS INCYTE CORPORATION 2022-07-07 US disclosed
EP-3697789-B1 CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS INCYTE CORP (US) 2021-09-29 EP disclosed
EP-3697789-B1 CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS INCYTE CORP (US) 2021-09-29 EP disclosed
US-20200385392-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS INCYTE CORPORATION 2020-12-10 US disclosed
US-20200385392-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS INCYTE CORPORATION 2020-12-10 US disclosed
CN-111542526-A Condensed imidazole derivatives substituted by tertiary hydroxyl group as PI 3K-gamma inhibitor 因赛特公司 2020-08-14 CN disclosed
US-10738057-B2 Tertiary alcohols as PI3K-γ inhibitors INCYTE CORPORATION (US) 2020-08-11 US disclosed
US-10738057-B2 Tertiary alcohols as PI3K-γ inhibitors INCYTE CORPORATION (US) 2020-08-11 US disclosed
US-20190152975-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS INCYTE CORPORATION 2019-05-23 US disclosed
US-20190152975-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS INCYTE CORPORATION 2019-05-23 US disclosed
WO-2019079469-A1 CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED BY TERTIARY HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS INCYTE CORPORATION (US) 2019-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228498-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS PIK3R5, PIK3R1, PIK3CD CDK1 2462/4885CSNK1A1 1701/4885CLK4 4042/4885
US-20190152975-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS PIK3R5, PIK3R1, PIK3CD CDK1 2462/4885CSNK1A1 1701/4885CLK4 4042/4885
US-10738057-B2 Tertiary alcohols as PI3K-γ inhibitors PIK3R5, PIK3CG, PIK3CD CDK1 2359/4885CSNK1A1 1664/4885CLK4 4459/4885
US-20220213107-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS PIK3R5, PIK3R1, PIK3CD CDK1 2462/4885CSNK1A1 1701/4885CLK4 4042/4885
US-20200385392-A1 TERTIARY ALCOHOLS AS PI3K-y INHIBITORS PIK3R5, PIK3R1, PIK3CD CDK1 2462/4885CSNK1A1 1701/4885CLK4 4042/4885
US-12281119-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist TLR7, TLR1, TLR3 CDK1 2702/4885CSNK1A1 87/4885CLK4 924/4885
US-11926630-B2 Tertiary alcohols as PI3K-γ inhibitors PIK3R5, PIK3CG, PIK3CD CDK1 2359/4885CSNK1A1 1664/4885CLK4 4459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.